Mitigating the Risk of Transfusion-Transmitted Dengue in Australia

• Published in: Journal of blood transfusion 2016-01, Vol.2016, p.1-6
• Main Authors: Rooks, Kelly, Seed, Clive R., Fryk, Jesse J., Hyland, Catherine A., Harley, Robert J., Holmberg, Jerry A., Marks, Denese C., Flower, Robert L. P., Faddy, Helen M.
• Format: Article
• Language: English
• ISSN: 2090-9187; 2090-9195
• DOI: 10.1155/2016/3059848

Dengue viruses (DENV 1–4) are a risk to transfusion safety, with several transfusion-transmitted (TT) cases reported globally. DENV 1–4 are endemic in over 100 countries, with seasonal outbreaks occurring in northeastern Australia. To mitigate TT-DENV risk in Australia, fresh blood components are not manufactured from donors returning from any area (domestic/overseas) with known dengue transmission. Alternatively, TT-DENV risk may be mitigated using an appropriate blood donor screening assay. We aimed to determine the rate of dengue infection in donors during dengue outbreaks in Australia. Plasma samples were collected from blood donors during local dengue outbreaks. All samples were tested for the presence of DENV RNA and selected samples were tested for DENV antigen (nonstructural protein 1, NS1) with two assays. No donors residing in high risk areas had detectable levels of DENV RNA or NS1 and no cases of DENV viremia were detected in blood donors residing in areas of Australia experiencing DENV outbreaks. Definitive conclusions could not be drawn from this study; however, the lack of detection of DENV RNA or antigen in donations suggests that the current risk of TT-DENV is low and maintaining the fresh component restriction for “at-risk” donors is appropriate.